— Abstracts Report on Screening Population for PALISADE Phase 3
Clinical Trial and Current Management of Peanut Allergy —
BRISBANE, California--(BUSINESS WIRE)--Jun. 15, 2017--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, announced
today that it will present data during poster sessions on Tuesday, June
20, at the 2017 European Academy of Allergy and Clinical Immunology
(EAACI) Congress, taking place June 16–21 in Helsinki.
The presentations will report clinical data from the European screening
population of the PALISADE Phase 3 trial in Aimmune’s AR101 program
(Abstract 0371) and observations on current management and use of oral
immunotherapy for peanut allergy across Western Europe (Abstract 1369).
AR101 is Aimmune’s investigational biologic oral immunotherapy for
desensitization of patients with peanut allergy.
Presentation details are as follows:
Abstract 0371: Vereda A, et al., Clinical and immunologic
characteristics of European patients screened for PALISADE (Peanut
Allergy Oral Immunotherapy Study of AR101
for Desensitization in Children and Adults)
Discussion Session 21, Immunotherapy: News from the clinic
a.m.–12:00 Eastern European Time, Tuesday, June 20, 2017, Poster
Discussion Zone 1, Messukeskus Helsinki
Abstract 1369: Radwan A, et al., Current Management and
Use of Oral Immunotherapy for Peanut Allergy Across Western Europe
Poster Session 53, Risk Factors and management of food allergy
p.m. Eastern European Time, Tuesday, June 20, 2017, Poster Exhibition
Area, Messukeskus Helsinki
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of protection
by desensitizing patients with defined, precise amounts of key
allergens. Aimmune’s first investigational biologic product using
CODIT™, AR101 for the treatment of peanut allergy, has received the
FDA’s Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4-17 years of age and is currently being
evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or the European Medicines Agency
(EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170615005417/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,